Spruce Biosciences, Inc. SPRB · Stock Open Spruce Biosciences, Inc. in new tab
Spruce Biosciences, Inc. Analysis (SPRB)
Is Spruce Biosciences, Inc. a good investment? Spruce Biosciences, Inc. (SPRB) is currently trading at 0.6772 USD. Market analysts have a consensus price target of 2.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Spruce Biosciences, Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.96.
Investor FAQ
Does Spruce Biosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Spruce Biosciences, Inc.?
Spruce Biosciences, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -1.24.
Company Profile
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Community Discussion